The U.S. Food and Drug Administration issued a pair of documents clarifying its interpretation of the Biologics Price Competition and Innovation Act (BPCI Act). The agency reissued its final "Questions and Answers on Biosimilar Development" guidance to withdraw three specific Q&As and simultaneously posted a revised draft Q&A document to update interpretations and facilitate biosimilar development. The reissued final guidance withdraws Q&As I.8, I.10, and I.19 and signals FDA ongoing evaluation of other Q&As to reflect current thinking. The draft revision provides industry stakeholders with updated explanations on interchangeability, analytical similarity, and regulatory pathways under the BPCI Act. Sponsors and biosimilar developers will need to parse the revisions to align development programs and submissions; the move reflects FDA efforts to refine regulatory clarity as competition in biologics and biosimilars increases.